Patents by Inventor Thomas Emmons

Thomas Emmons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7732183
    Abstract: The invention provides methods for efficient recombinant expression, refolding, and purification of Beta-site APP cleaving enzyme (BACE) polypeptides. In various aspects, the method includes the steps of expressing a recombinant construct in bacteria, dissolving inclusion bodies with a denaturant at high pH in the presence of a reducing agent, diluting the solubilized BACE polypeptide in an aqueous solution at a temperature of about 1° C. to 15° C., and incubating the diluted sample at a temperature of about 4° C. to 15° C. until the recombinant BACE polypeptide folds into an active enzyme.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: June 8, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Alfredo Tomasselli, Robert Heinrikson, Donna Paddock, Ana Mildner, Thomas Emmons
  • Publication number: 20080090260
    Abstract: The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a ?-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.
    Type: Application
    Filed: May 24, 2007
    Publication date: April 17, 2008
    Inventors: Riqiang Yan, Alfredo Tomasselli, Mark Gurney, Thomas Emmons, Michael Bienkowski, Robert Heinrikson
  • Patent number: 7186539
    Abstract: The invention provides methods for efficient recombinant expression, refolding, and purification of Beta-site APP cleaving enzyme (BACE) polypeptides. In various aspects, the method includes the steps of expressing a recombinant construct in bacteria, dissolving inclusion bodies with a denaturant at high pH in the presence of a reducing agent, diluting the solubilized BACE polypeptide in an aqueous solution at a temperature of about 1° C. to 15° C., and incubating the diluted sample at a temperature of about 4° C. to 15° C. until the recombinant BACE polypeptide folds into an active enzyme.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: March 6, 2007
    Assignee: Pharmacia & UpJohn Company
    Inventors: Alfredo Tomasselli, Robert Heinrikson, Donna Paddock, Ana Mildner, Thomas Emmons
  • Publication number: 20060221871
    Abstract: A method for minimizing the number of transcoders needed to support group calls includes a first step of receiving a request from a call initiator to initiate a group call with a plurality of call targets. Next, a listing of call initiator vocoders supported by the call initiator is received. Then, a call invitation is sent to each of a plurality of networks associated with the call targets. Network responses are received from each of the plurality of networks. The network responses comprise one or more network supported vocoders. The responses from all of the plurality of networks are collected. Then, the amount of transcoder needed to support the group call is optimized by minimizing the number of call initiator vocoders and network supported vocoder pairs.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 5, 2006
    Inventors: Thomas Emmons, Janus Burks, Brian Towey
  • Publication number: 20060146794
    Abstract: These teachings facilitate interaction between two or more communication networks (10 and 11) comprising separate and discrete communication system peers. At least one of these networks is functionally partitioned with respect to interrogation and call signaling procedures over a plurality of geographic service areas (14, 15, and 16). Gateways (12 and 13) permit interaction between these networks, wherein at least some of the gateways provide functionally partitioned interrogation and call signaling procedures for some, but not all, of the plurality of geographic service areas. Upon receiving (32) a call routing message from a source from a remote communication network, which message identifies a target communication unit that is currently serviced by the first communication network, such a gateway can process (33) that call routing message as a function, at least in part, of a home geographic service area and a serving geographic area as corresponds to the target communication unit.
    Type: Application
    Filed: December 30, 2004
    Publication date: July 6, 2006
    Inventors: William Shores, Thomas Emmons, Thomas Hallin, Leonard Pennock, J.C. Stanaway
  • Publication number: 20050240674
    Abstract: The present method provides for a session initiation protocol timing arrangement which facilitates instant communications in a packet data communication system (50). Each network server (15-25) sets a time out timer (92) which is coordinated with each of the downstream network servers. Network server (15), for example, sets a time out timer value which is selectable by the system operator. Subsequent network servers (20 and 25) then set the value of the time out timer to be that of the originating server (15) or client (10) less a fixed time such as one second. Further, a provisional message (118) is sent through the network to avoid expiration of the time out timer in upstream stages.
    Type: Application
    Filed: April 23, 2004
    Publication date: October 27, 2005
    Inventors: Louis Depalma, Rose Dees, Thomas Emmons
  • Publication number: 20050237999
    Abstract: For a network server (35) communicating with a wireless unit (10) via a Session Initiation Protocol, a retransmission method (50) first sets a timer based upon a time likely for a mobile unit to respond (54). Then the network server waits for a response (56). When the timer set for the kind of mobile unit being used expires (64), a retransmit of the original SIP request takes place (68). Optionally, modes for waiting may include a linear mode (72) and an exponential mode (74).
    Type: Application
    Filed: April 23, 2004
    Publication date: October 27, 2005
    Inventors: William Shores, Nandakishore Albal, Louis Depalma, Thomas Emmons, Derek Oxley
  • Publication number: 20050096457
    Abstract: The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a ?-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.
    Type: Application
    Filed: March 16, 2004
    Publication date: May 5, 2005
    Applicant: Pharmacia & Upjohn Company, a Delaware corporation
    Inventors: Riqiang Yan, Alfredo Tomasselli, Mark Gurney, Thomas Emmons, Michael Bienkowski, Robert Heinrikson
  • Publication number: 20040152900
    Abstract: The present invention is directed to the method of isolation of sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester, a metabolite of the 5HT2A antagonist (+)-&agr;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
    Type: Application
    Filed: January 20, 2004
    Publication date: August 5, 2004
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Ronald Charles Bernotas, Paul Wayne Brown, Gary Thomas Emmons, Chi-Hsin Richard King
  • Patent number: 6716986
    Abstract: The present invention is directed to sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester, a metabolite of the 5HT2A antagonist (+)-&agr;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and a processes for its preparation and its use in the treatment for a number of disease states.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: April 6, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Ronald Charles Bernotas, Paul Wayne Brown, Gary Thomas Emmons, Chi-Hsin Richard King
  • Patent number: 6465490
    Abstract: The present invention is directed to sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester a metabolite of the 5HT2A antagonist (+)-&agr;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and a processes for its preparation and its use in the treatment for a number of disease states.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: October 15, 2002
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Ronald Charles Bernotas, Paul Wayne Brown, Gary Thomas Emmons, Chi-Hsin Richard King